Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.11.013PMID 16135470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

  2004cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

  2004cited by this paper
• Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel.

  2004cited by this paper
• Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

  2003cited by this paper
• Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.

  2003cited by this paper
• Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung.

  2003cited by this paper
• Caveolae: mining little caves for new cancer targets

  2003cited by this paper
• Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

  2002cited by this paper
• Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albumin in Vivo *

  2001cited by this paper
• Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

  2001cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.

  1999cited by this paper
• Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

  1999cited by this paper
• Elevated expression of caveolin is associated with prostate and breast cancer.

  1998cited by this paper
• Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

  1998cited by this paper
• Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

  1996cited by this paper
• Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

  1995cited by this paper
• Optic nerve disturbances: a new form of paclitaxel neurotoxicity.

  1994cited by this paper
• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

  1993cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Hypersensitivity reactions from taxol.

  1990cited by this paper
• How large should a phase II trial of a new drug be?

  1987cited by this paper
• Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

  1977cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Antitumor Efficacy of Paclitaxel Injection Concentrate for Nanodispersion in Patient-Derived Breast, Head and Neck, and Non-Small Cell Lung Cancer Mouse Xenografts

  2025cites this paper
• Albumin-based nanocarriers: Singularities, synthesis methods, clinical relevance and targeting strategies in cancer

  2025cites this paper
• Wolf in Sheep’s Clothing: Taming Cancer’s Resistance with Human Serum Albumin?

  2025cites this paper
• Developments in nanotechnology approaches for the treatment of solid tumors

  2025cites this paper
• Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives.

  2024cites this paper
• Management of infusion-related reactions in cancer therapy: strategies and challenges

  2024cites this paper
• Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma.

  2024cites this paper
• Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study

  2024cites this paper
• Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel

  2024cites this paper
• Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer

  2024cites this paper
• Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects

  2024cites this paper
• A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case–control study

  2024cites this paper
• A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.

  2024cites this paper
• Advancing Tumor Therapy: Development and Utilization of Protein-Based Nanoparticles

  2024cites this paper
• Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study

  2024cites this paper
• Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective

  2023cites this paper
• Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy

  2023cites this paper
• The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence

  2023cites this paper
• Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives.

  2023cites this paper
• Continuous Manipulation and Characterization of Colloidal Beads and Liposomes via Diffusiophoresis in Single- and Double-Junction Microchannels

  2023cites this paper
• Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

  2022cites this paper
• Triple negative breast cancer: approved treatment options and their mechanisms of action

  2022cites this paper
• The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine

  2022cites this paper
• Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.

  2022cites this paper
• A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer

  2021cites this paper
• Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

  2021cites this paper
• Retinal toxicities of Systemic Anticancer Drugs.

  2021cites this paper
• Surface modified receptor mediated delivery systems for site specific treatment of cancer

  2021cites this paper
• Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

  2021cites this paper
• Targeting Engineered Nanoparticles for Breast Cancer Therapy

  2021cites this paper
• Assessing taxane-associated adverse events using the FDA adverse event reporting system database

  2021cites this paper
• Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer

  2021cites this paper
• Nanotechnology for cancer drug design, delivery, and theranostics applications

  2021cites this paper
• Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals.

  2021cites this paper
• Tackling the challenges of nanomedicines: are we ready?

  2021cites this paper
• Hypersensitivity Reactions to Platinum Agents and Taxanes

  2021cites this paper
• Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study.

  2021cites this paper
• The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.

  2021cites this paper
• Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

  2021cites this paper
• Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer.

  2021cites this paper
• Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

  2021cites this paper
• Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.

  2020cites this paper
• Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer

  2020cites this paper
• Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

  2020cites this paper
• Formulation and Evaluation of Protein Bound Paclitaxel Nanoparticles for Injectable Suspension

  2020cites this paper
• Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics.

  2020cites this paper
• A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

  2020cites this paper
• Taxane anticancer formulations: challenges and achievements

  2020cites this paper
• A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer

  2020cites this paper
• Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System

  2019cites this paper
• Efficacy of nab-paclitaxel in treating metastatic melanoma

  2019cites this paper
• Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).

  2019cites this paper
• EFFICACY AND SAFETY OF NANOPARTICLE ALBUMIN-BOUND PACLITAXEL VERSUS PACLITAXEL IN METASTATIC BREAST CANCER

  2019cites this paper
• Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer

  2019cites this paper
• Clinical characteristics of colitis induced by taxane-based chemotherapy

  2019cites this paper
• nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

  2019cites this paper
• Effects of block copolymer micelles on the pharmacokinetics of encapsulated drugs

  2019cites this paper
• Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

  2019cites this paper
• Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.

  2018cites this paper
• A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.

  2018cites this paper
• Delivery of Cancer Nanotherapeutics

  2018cites this paper
• Taxane formulations: From plant to clinic

  2018cites this paper
• Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer

  2018cites this paper
• Repositioning Microtubule Stabilizing Drugs for Brain Disorders

  2018cites this paper
• Management of Metastatic Triple-Negative Breast Cancer

  2018cites this paper
• Chemotherapeutic drug delivery by tumoral extracellular matrix targeting.

  2018cites this paper
• Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

  2018cites this paper
• Feasibility Study of Weekly Nanoparticle Albumin‐Bound Paclitaxel (150 mg/m2) Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Therapy as Neoadjuvant Chemotherapy for HER2‐Negative Breast Cancer

  2018cites this paper
• Final Effectiveness and Safety Results of NABUCCO: Real‐World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab‐Paclitaxel

  2018cites this paper
• Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases

  2018cites this paper
• A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer

  2018cites this paper
• Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy.

  2018cites this paper
• Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

  2018cites this paper
• Albumin-covered lipid nanocapsules exhibit enhanced uptake performance by breast-tumor cells.

  2018cites this paper
• Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents

  2017cites this paper
• Liquid formulation containing doxorubicin-loaded lipid-core nanocapsules: Cytotoxicity in human breast cancer cell line and in vitro uptake mechanism.

  2017cites this paper
• Systemic Drug Delivery in Gastric Cancer

  2017cites this paper
• A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer

  2017cites this paper
• Retrospective Audit on the use of Albumin-Bound Paclitaxel (Nab-Paclitaxel) and it`s Outcomes in Dubai Hospital

  2017cites this paper
• Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial

  2017cites this paper
• Incidence and risk of peripheral neuropathy with nab‐paclitaxel in patients with cancer: a meta‐analysis

  2017cites this paper
• Avoiding the mononuclear phagocyte system using human albumin for mesoporous silica nanoparticle system

  2017cites this paper
• Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments

  2017cites this paper
• Developments and future clinical outlook of taxane nanomedicines.

  2017cites this paper
• Paclitaxel: What has been done and the challenges remain ahead.

  2017cites this paper
• Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

  2016cites this paper
• Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.

  2016cites this paper
• Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

  2016cites this paper
• Chemotherapy‐mediated pain and peripheral neuropathy: impact of oxidative stress and inflammation

  2016cites this paper
• Nanomedicines for renal disease: current status and future applications

  2016cites this paper
• A case of hemorrhagic cystitis caused by nab-paclitaxel

  2016cites this paper
• Development and testing of multi-modal, multi-scale imaging systems for rare-earth-doped contrast agents

  2016cites this paper
• Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions.

  2016cites this paper
• Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

  2016cites this paper
• A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

  2016cites this paper
• Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.

  2016cites this paper
• Albumin anchored docetaxel lipid nanoemulsion for improved targeting efficiency – preparation, characterization, cytotoxic, antitumor and in vivo imaging studies

  2016cites this paper
• Abstract P1-13-05: GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses

  2016cites this paper